GlassScriptPhysician profile
James B Wilson
NPI 1992747034
$10,223.97
in general payments reported to CMS, 2019-2025
58 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $502 · 2021: $1,360 · 2022: $1,902 · 2023: $1,819 · 2024: $1,815 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,036 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,035.54 |
| Education | $109.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,432.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,401.50 | 2019-2025 | Vraylar, Qulipta, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,036.50 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $716.18 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $481.51 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $405.76 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $363.52 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.85 | 2019-2025 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $270.74 | 2020-2025 | Seglentis, Zoryve |
| Glaxosmithkline, LLC. | $264.49 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $228.87 | 2023-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $211.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $207.14 | 2019-2023 | Spravato, Xarelto |
| Axsome Therapeutics, INC. | $188.82 | 2023-2025 | Sunosi, Auvelity |
| Exact Sciences Corporation | $183.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.